GEN-Y Biologics Overview
- Year Founded
-
2020
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
GEN-Y Biologics General Information
Description
Developer of a dengue antibody development company intended to screen human memory B-cells from convalescent patients. The company uses a blend of bioinformatics and parallel sequencing to develop a COVID Omicron immunity test that identifies an individual's risk of infection by COVID viral variants, enabling patients to reduce or block infection SARS virus.
Contact Information
Website
www.genybiologics.comCorporate Office
- 2 Havelock Road, Havelock2
- Suite 06-01
- Singapore, 059763
- Singapore
Corporate Office
- 2 Havelock Road, Havelock2
- Suite 06-01
- Singapore, 059763
- Singapore
GEN-Y Biologics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Out of Business | 23-Sep-2025 | Completed | Out of Business | |||
| 1. Accelerator/Incubator | 01-Jan-2023 | Completed | Generating Revenue |
GEN-Y Biologics FAQs
-
When was GEN-Y Biologics founded?
GEN-Y Biologics was founded in 2020.
-
Where is GEN-Y Biologics headquartered?
GEN-Y Biologics is headquartered in Singapore, Singapore.
-
What industry is GEN-Y Biologics in?
GEN-Y Biologics’s primary industry is Biotechnology.
-
Is GEN-Y Biologics a private or public company?
GEN-Y Biologics is a Private company.
-
What is GEN-Y Biologics’s current revenue?
The current revenue for GEN-Y Biologics is .
-
How much funding has GEN-Y Biologics raised over time?
GEN-Y Biologics has raised $1.6M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process